Business
Medexus Pharmaceuticals Announces Closing of $30 Million Overnight Marketed Public Offering of Common Shares
Toronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuti...
About this update from Medexus Pharmaceuticals Inc.
[{"type":"text","content":"Medexus Pharmaceuticals Announces Closing of $30 Million Overnight Marketed Public Offering of Common SharesToronto, Ontario and Chicago, Illinois--(Newsfile Corp. - January 31, 2025) - Medexus Pharmaceuticals Inc. (TSX: MDP) (\"Medexus\" or the \"Company\"), is pleased to announce the closing of its previously announced overnight marketed underwritten offering (the \"Offering\") of 7,500,000 common shares of the Company (the \"Common Shares\") at a public offering price of $4.00 per Common Share for aggregate gross proceeds to the Company of $30,000,000. The Offering was completed pursuant to an underwriting agreement dated January 28, 2025 between Medexus and Raymond James Ltd., as lead underwriter and sole bookrunner, on behalf of a syndicate of underwriters, which included Research Capital Corporation, A.G.P. Canada Investments ULC, Bloom Burton Securities Inc., Canaccord Genuity Corp., and Leede Financial Inc.The Company expects that the net proceeds of the Offering will be used: (i) to repay a US$2.5 million credit received from medac in September 2021 and pay a portion of the milestone payment amount to medac, and (ii) for working capital and general corporate purposes, which may include funding the Company's ongoing business development activities and initiatives.The Common Shares were offered in each of the provinces and territories of Canada, other than Québec, pursuant to a prospectus supplement (the \"Prospectus Supplement\") dated January 28, 2025 filed under Medexus' short form base shelf prospectus dated November 15, 2024. The terms of the Offering are described in the Prospectus Supplement, which is available under Medexus' profile on SEDAR+ at www.sedarplus.ca.The securities have not been, and will not be, registered under the United States Securities Act of 1933, as amended (the \"U.S. Securities Act\"), or any U.S. state securities laws, and may not be offered or sold in the \"United States\" (as such term is defined in Regulation S under the U.S. Securities Act) without registration under the U.S. Securities Act and all applicable U.S. state securities laws or compliance with the requirements of an applicable exemption therefrom. This press release shall not constitute an offer to sell or the solicitation of an offer to buy securities in the United States, nor shall there be any sale of these securities ...